SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality.

Machado, RD; Welch, CL; Haimel, M; Bleda, M; Colglazier, E; Coulson, JD; Debeljak, M; Ekstein, J; Fineman, JR; Golden, WC; et al. Machado, RD; Welch, CL; Haimel, M; Bleda, M; Colglazier, E; Coulson, JD; Debeljak, M; Ekstein, J; Fineman, JR; Golden, WC; Griffin, EL; Hadinnapola, C; Harris, MA; Hirsch, Y; Hoover-Fong, JE; Nogee, L; Romer, LH; Vesel, S; NIHR BioResource - Rare Diseases; Gräf, S; Morrell, NW; Southgate, L; Chung, WK (2022) Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality. J Med Genet, 59 (9). pp. 906-911. ISSN 1468-6244 https://doi.org/10.1136/jmedgenet-2021-107831
SGUL Authors: Southgate, Laura

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

BACKGROUND: The molecular genetic basis of pulmonary arterial hypertension (PAH) is heterogeneous, with at least 26 genes displaying putative evidence for disease causality. Heterozygous variants in the ATP13A3 gene were recently identified as a new cause of adult-onset PAH. However, the contribution of ATP13A3 risk alleles to child-onset PAH remains largely unexplored. METHODS AND RESULTS: We report three families with a novel, autosomal recessive form of childhood-onset PAH due to biallelic ATP13A3 variants. Disease onset ranged from birth to 2.5 years and was characterised by high mortality. Using genome sequencing of parent-offspring trios, we identified a homozygous missense variant in one case, which was subsequently confirmed to cosegregate with disease in an affected sibling. Independently, compound heterozygous variants in ATP13A3 were identified in two affected siblings and in an unrelated third family. The variants included three loss of function variants (two frameshift, one nonsense) and two highly conserved missense substitutions located in the catalytic phosphorylation domain. The children were largely refractory to treatment and four died in early childhood. All parents were heterozygous for the variants and asymptomatic. CONCLUSION: Our findings support biallelic predicted deleterious ATP13A3 variants in autosomal recessive, childhood-onset PAH, indicating likely semidominant dose-dependent inheritance for this gene.

Item Type: Article
Additional Information: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Keywords: genetics, pediatrics, pulmonary heart disease, 06 Biological Sciences, 11 Medical and Health Sciences, Genetics & Heredity
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: J Med Genet
ISSN: 1468-6244
Language: eng
Dates:
DateEvent
19 August 2022Published
7 September 2021Published Online
12 August 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
SBF005/1115Academy of Medical Scienceshttp://dx.doi.org/10.13039/501100000691
204809/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
BRC-1215-20014National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
PubMed ID: 34493544
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113689
Publisher's version: https://doi.org/10.1136/jmedgenet-2021-107831

Actions (login required)

Edit Item Edit Item